Century Therapeutics appoints Truitt. Century Therapeutics stock has USD 309.6 million value.

Published on 10/01/2026 at 11:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Century Therapeutics lost USD 34.6 million in the second quarter of 2026. Century Therapeutics stock is backed by USD 49.6 million cash on June 30, 2026.

IPSC, US15671W1045, Illustration mit AI erstellt.

Century Therapeutics (ISIN US15671W1045) appointed Joseph Truitt to its board on September 9, 2026, while the company had a market capitalization of USD 309.6 million on September 30, 2026. The appointment adds a biotechnology executive with experience in gene editing and clinical-stage drug development to the board.

Board expands during pipeline push

According to the SEC filing dated September 9, 2026, Century increased its board from six to seven directors and appointed Truitt as a Class I director. His term runs to the 2028 annual meeting, and he will serve on the compensation committee.

Truitt has served as chief executive officer of iECURE since March 2021 and previously held senior roles at Achillion Pharmaceuticals and BioSpecifics Technologies. Those companies were later acquired, giving the appointment a direct connection to gene-editing and biotechnology deal experience.

Second-quarter loss reaches USD 34.6 million

FinancialContent reported on August 12, 2026, that Century posted a net loss of USD 34.6 million for the second quarter ended June 30, 2026. The first half loss reached USD 56.2 million, compared with net income of USD 44.0 million in the first half of 2025, a shift that reflects the company's move toward pipeline investment rather than commercial revenue.

Research and development expenses fell to USD 19.6 million from USD 26.9 million in the prior-year quarter, while general and administrative expenses declined to USD 5.8 million from USD 7.8 million. Cash and cash equivalents stood at USD 49.6 million on June 30, 2026, and operating cash flow was negative USD 19.8 million in the second quarter.

Analyst view remains divided

According to MarketBeat on September 12, 2026, Wall Street Zen upgraded Century Therapeutics from Sell to Hold. The report placed the broader consensus at Hold and cited an average target of USD 4.75, while the latest reported quarterly earnings per share of negative USD 0.17 missed the consensus estimate of negative USD 0.11 by USD 0.06.

The company's main near-term development marker is CNTY-813, an induced pluripotent stem cell-derived therapy for type 1 diabetes. The September 2026 filing said an investigational new drug submission remains on track for the fourth quarter of 2026, while CNTY-308 is planned to enter the clinic during 2026.

Market value and operating profile

Century Therapeutics had a market capitalization of USD 309.6 million on September 30, 2026. Its 52-week range was USD 0.43 to USD 3.04, placing the latest structured quote within a wide biotechnology trading band. The company is listed on the Nasdaq Capital Market under ticker IPSC and operates in the Healthcare Biotechnology industry.